Tamika Scott
Adult Health · Columbia, MDNPI 1699314393
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 279 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 30 manufacturers reported payments, led by Collegium Pharmaceutical, Inc. at 49.4% of the total. Reporting peaked in 2021 at $1,215 and has fallen 69.1% since, to $376 in 2025. Among adult health clinicians in MD with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 279 payments — averaging $14.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Collegium Pharmaceutical, Inc.$2K
- Protega Pharmaceutials Inc$284
- Almatica Pharma LLC$282
- Nevro Corp.$167
- GRT US Holding, Inc.$157
- Electronic Waveform Lab, Inc.$133
- plus $1K from 24 others
What the payments were for
- Food & beverage$4,107100%
- Education$10%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Collegium Pharmaceutical, Inc. | 154 | $2,031 |
| Protega Pharmaceutials Inc | 17 | $284 |
| Almatica Pharma LLC | 19 | $282 |
| Nevro Corp. | 6 | $167 |
| GRT US Holding, Inc. | 7 | $157 |
| Electronic Waveform Lab, Inc. | 12 | $133 |
| Biodelivery Sciences International, Inc. | 15 | $125 |
| Redhill Biopharma Inc. | 5 | $91 |
| Eisai Inc. | 5 | $80 |
| Averitas Pharma Inc. | 3 | $76 |
| Scilex Pharmaceuticals Inc. | 4 | $76 |
| Boston Scientific | 3 | $73 |
| IBSA Pharma Inc. | 3 | $59 |
| Medtronic | 3 | $52 |
| Fidia Pharma USA Inc. | 3 | $49 |
| Spinal Simplicity, LLC | 2 | $48 |
| Johnson & Johnson | 2 | $47 |
| Pfizer | 2 | $34 |
| Cumberland Pharmaceuticals, Inc. | 1 | $29 |
| Idorsia Pharmaceuticals US Inc | 1 | $25 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $24 |
| Stimwave Technologies Incorporated | 2 | $24 |
| Si-bone, Inc. | 1 | $23 |
| AbbVie | 1 | $22 |
| Mallinckrodt Hospital Products Inc. | 1 | $20 |
| Virtus Pharmaceuticals LLC | 1 | $17 |
| Convatec Inc. | 1 | $17 |
| Hikma Pharmaceuticals USA | 1 | $17 |
| Vertos Medical, Inc. | 1 | $14 |
| Amgen | 1 | $12 |
How this compares
$4,107 in reported general payments places this provider in the 90th percentile of 542 adult health providers in Maryland.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OxycontinOxycodone Hcl | 113 | $80,744 |
| Xtampza ErOxycodone Myristate | 112 | $76,578 |
| BelbucaBuprenorphine Hcl | 58 | $61,808 |
| NucyntaTapentadol Hcl | 35 | $30,268 |
| Oxycodone Hcl | 1,232 | $27,120 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 506 | $14,887 |
| Nucynta ErTapentadol Hcl | 13 | $12,939 |
| Oxymorphone Hcl ErOxymorphone Hcl | 25 | $9,854 |
| MovantikNaloxegol Oxalate | 22 | $9,549 |
| Fentanyl | 116 | $9,391 |
| Diclofenac Sodium | 98 | $9,390 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 337 | $8,222 |
| Pregabalin | 276 | $7,383 |
| Lidocaine | 56 | $6,340 |
| Morphine Sulfate ErMorphine Sulfate | 214 | $5,228 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Collegium Pharmaceutical, Inc.Xtampza Er, Belbuca, Nucynta, Nucynta Er | $2,031 | $181,594218 claims |
| Redhill Biopharma Inc.Movantik | $91 | $9,54922 claims |
| Hikma Pharmaceuticals USABuprenorphine, Morphine Sulfate | $17 | $3,72069 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 542 adult health providers in Maryland.
Other adult health in Columbia
- Lucia NovakCamp Springs$473K
- Caroline RuhlAnnapolis$315K
- Joyce MiskovicHighland$264K
- Christopher RobersonBaltimore$180K
- Amit DhirBaltimore$97K
- Morgan JoliatSykesville$92K
- Brendon BowerBaltimore$64K
- Caitlin NassBaltimore$46K
- Jane KapustinClarksville$44K
- Sarah RileyBaltimore$24K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.